Lista de obras - Ira Shoulson - Dominio Público Uruguay

A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease

artículo científico publicado en 2017

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts

artículo científico

A longitudinal program for biomarker development in Parkinson's disease: a feasibility study

artículo científico publicado en 2009

A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease

scientific article published on 01 January 1994

A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).

artículo científico publicado en 2017

A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study

artículo científico publicado en 2014

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit

artículo científico

A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations

artículo científico publicado en 2006

A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease

artículo científico publicado en 2001

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease

artículo científico

A study of chorea after tetrabenazine withdrawal in patients with Huntington disease

artículo científico publicado en 2008

Altered cholesterol and fatty acid metabolism in Huntington disease ⬇️

artículo científico publicado el 1 de enero de 2010

Approaches and costs for sharing clinical research data

artículo científico publicado en 2014

Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease

artículo científico publicado en 2015

Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease

artículo científico publicado en 2007

Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease

artículo científico publicado en 2010

Case 1, 1989: juvenile-onset parkinsonism, dystonia, and pyramidal tract signs

artículo científico publicado en 1989

Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS ⬇️

artículo científico publicado el 26 de abril de 2013

Clinical markers of early disease in persons near onset of Huntington's disease.

artículo científico publicado en 2001

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials

artículo científico publicado en 2015

Communicating clinical trial results to research participants

artículo científico publicado en 2008

Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person

scientific article published on 01 January 2020

Congresswoman Louise M. Slaughter (1929–2018)

Data sharing for public health research: A qualitative study of industry and academia

artículo científico publicado en 2014

Deep Phenotyping of Parkinson's Disease

artículo científico publicado en 2020

Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study

artículo científico publicado en 2013

Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD)

artículo científico publicado en 2020

Detection of Huntington's disease decades before diagnosis: the Predict-HD study ⬇️

artículo científico publicado en 2007

Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants

artículo científico publicado en 2009

Disease Progression in Huntington Disease: An Analysis of Multiple Longitudinal Outcomes

artículo científico publicado en 2018

Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments

artículo científico publicado en 2006

Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease

artículo científico publicado en 2012

Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease

artículo científico publicado en 2015

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

artículo científico publicado en 2002

Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline

artículo científico publicado en 2006

Erratum to: Inaugural Conference on Incorporating Patient-Reported Outcomes and Patient Preference Information into Clinical Research, Clinical Care, and Risk-Benefit Assessments for Neurodegenerative Diseases.

artículo científico publicado en 2017

Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at-risk observational study (PHAROS).

artículo científico publicado en 2016

Fear of health insurance loss among individuals at risk for Huntington disease

scientific article published on 01 August 2008

Genetic Adverse Selection: Evidence from Long-Term Care Insurance and Huntington Disease ⬇️

Genetic Risk Underlying Psychiatric and Cognitive Symptoms in Huntington's Disease

scientific article published on 17 December 2019

HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD).

artículo científico publicado en 2016

HTRF analysis of soluble huntingtin in PHAROS PBMCs ⬇️

artículo científico publicado el 21 de agosto de 2013

High-dosage vitamin E supplementation and all-cause mortality

artículo científico publicado en 2005

Huntington disease: Clinical care and evaluation ⬇️

artículo científico publicado el 1 de enero de 1979

Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics

artículo científico publicado en 2009

I-SPY 2 Breast Cancer Trial as a Model for Innovation in Alzheimer Disease Therapies

artículo científico publicado en 2017

Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial

artículo científico publicado en 2014

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

artículo científico publicado en 2002

In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study

artículo científico publicado en 2010

Inaugural Conference on Incorporating Patient-Reported Outcomes and Patient Preference Information into Clinical Research, Clinical Care, and Risk-Benefit Assessments for Neurodegenerative Diseases

artículo científico publicado en 2017

Inaugural Huntington Disease Clinical Research Symposium Organized by the Huntington Study Group.

artículo científico publicado en 2008

Informativeness of Early Huntington Disease Signs about Gene Status.

artículo científico publicado en 2015

Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience

artículo científico publicado en 2020

Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial

artículo científico publicado en 2014

Interrater agreement in the assessment of motor manifestations of Huntington's disease

artículo científico publicado en 2005

Juvenile-onset huntington disease: a matter of perspective

artículo científico publicado en 2007

Levodopa and the progression of Parkinson's disease

artículo científico publicado en 2004

Limited Life Expectancy, Human Capital and Health Investments

artículo científico publicado en 2013

Limited Life Expectancy, Human Capital and Health Investments: Evidence from Huntington Disease ⬇️

artículo científico publicado en 2012

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

artículo científico publicado en 2014

Measuring the effects of therapy in Parkinson disease

artículo científico publicado en 2004

Mendelian randomization of serum urate and parkinson disease progression

artículo científico publicado en 2014

Milestones in huntington disease

artículo científico publicado en 2011

Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments

artículo científico publicado en 2013

Optimal Expectations and Limited Medical Testing: Evidence from Huntington Disease ⬇️

artículo científico publicado en 2011

Optimal Expectations and Limited Medical Testing: Evidence from Huntington Disease: Corrigendum

artículo científico publicado en 2016

Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study

artículo científico publicado en 2010

Pharmacotherapy Use for Non-Motor Symptoms Among de novo Parkinson's Disease Parkinson's Progression Markers Initiative Participants

artículo científico publicado en 2020

Phenotype-genotype discrepancies in the prospective Huntington at-risk observational study

scientific article published on 01 May 2019

Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions

artículo científico publicado en 2008

Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10

artículo científico publicado en 2012

Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study

artículo científico publicado en 2015

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial

artículo científico publicado en 2004

Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts

artículo científico

Predictors of nursing home placement in Huntington disease

artículo científico publicado en 2003

Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts

artículo científico

Preempting genetic discrimination and assaults on privacy: report of a symposium

scientific article published on 01 August 2003

Preparing for preventive clinical trials: the Predict-HD study

artículo científico publicado en 2006

Rasagiline improves quality of life in patients with early Parkinson's disease

artículo científico publicado en 2006

Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms

artículo científico publicado en 2006

Rate of functional decline in Huntington's disease. Huntington Study Group

artículo científico publicado en 2000

Reasons for Premature Conclusion of Late Phase Clinical Trials: An Analysis of ClinicalTrials.gov Registered Phase III Trials

scientific article published on 06 January 2020

Reasons for Premature Conclusion of Late Phase Clinical Trials: An Analysis of ClinicalTrials.gov Registered Phase III Trials

scientific article published on 21 February 2019

Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease

article by Karen Marder et al published November 2013 in JAMA Neurology

Reply: Unusual DAT scan results

artículo científico publicado en 2013

Risk Factors for Suicidal Ideation in People at Risk for Huntington's Disease

artículo científico publicado en 2016

Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects

artículo científico publicado en 2010

Safety of rasagiline in elderly patients with Parkinson disease

artículo científico publicado en 2006

Second Annual Huntington Disease Clinical Research Symposium: Organized by the Huntington Study Group.

artículo científico publicado en 2009

Selected health and lifestyle factors, cytosine-adenine-guanine status, and phenoconversion in Huntington's disease

artículo científico publicado en 2018

Serum urate and probability of dopaminergic deficit in early "Parkinson's disease".

artículo científico publicado en 2011

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease

artículo científico publicado en 2008

TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease

artículo científico publicado en 2012

Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial

artículo científico publicado en 2002

The Prospective Huntington At-Risk Observational Study (PHAROS): The Emotional Well-Being, Safety and Feasibility of Long-Term Research Participation

artículo científico publicado en 2019

The choice not to undergo genetic testing for Huntington disease: Results from the PHAROS study

scientific article published on 15 May 2019

The relationship between CAG repeat length and clinical progression in Huntington's disease

artículo científico publicado en 2008

The role of mitochondrial DNA in Huntington's disease.

artículo científico publicado en 1989

Toward more efficient clinical trials for amyotrophic lateral sclerosis

artículo científico publicado en 2010

Urate as a predictor of the rate of clinical decline in Parkinson disease

artículo científico publicado en 2009

Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study

artículo científico publicado en 2011

Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset

scholarly article

Verbal episodic memory declines prior to diagnosis in Huntington's disease

artículo científico publicado en 2007

Weight loss in early stage of Huntington's disease

artículo científico publicado en 2002

Lista de obras de Ira Shoulson

A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts

A longitudinal program for biomarker development in Parkinson's disease: a feasibility study

A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease

A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).

A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit

A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations

A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease

A study of chorea after tetrabenazine withdrawal in patients with Huntington disease

Altered cholesterol and fatty acid metabolism in Huntington disease ⬇️

Approaches and costs for sharing clinical research data

Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease

Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease

Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease

Case 1, 1989: juvenile-onset parkinsonism, dystonia, and pyramidal tract signs

Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS ⬇️

Clinical markers of early disease in persons near onset of Huntington's disease.

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials

Communicating clinical trial results to research participants

Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person

Congresswoman Louise M. Slaughter (1929–2018)

Data sharing for public health research: A qualitative study of industry and academia

Deep Phenotyping of Parkinson's Disease

Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study

Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD)

Detection of Huntington's disease decades before diagnosis: the Predict-HD study ⬇️

Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants

Disease Progression in Huntington Disease: An Analysis of Multiple Longitudinal Outcomes

Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments

Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease

Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline

Erratum to: Inaugural Conference on Incorporating Patient-Reported Outcomes and Patient Preference Information into Clinical Research, Clinical Care, and Risk-Benefit Assessments for Neurodegenerative Diseases.

Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at-risk observational study (PHAROS).

Fear of health insurance loss among individuals at risk for Huntington disease

Genetic Adverse Selection: Evidence from Long-Term Care Insurance and Huntington Disease ⬇️

Genetic Risk Underlying Psychiatric and Cognitive Symptoms in Huntington's Disease

HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD).

HTRF analysis of soluble huntingtin in PHAROS PBMCs ⬇️

High-dosage vitamin E supplementation and all-cause mortality

Huntington disease: Clinical care and evaluation ⬇️

Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics

I-SPY 2 Breast Cancer Trial as a Model for Innovation in Alzheimer Disease Therapies

Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study

Inaugural Conference on Incorporating Patient-Reported Outcomes and Patient Preference Information into Clinical Research, Clinical Care, and Risk-Benefit Assessments for Neurodegenerative Diseases

Inaugural Huntington Disease Clinical Research Symposium Organized by the Huntington Study Group.

Informativeness of Early Huntington Disease Signs about Gene Status.

Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience

Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial

Interrater agreement in the assessment of motor manifestations of Huntington's disease

Juvenile-onset huntington disease: a matter of perspective

Levodopa and the progression of Parkinson's disease

Limited Life Expectancy, Human Capital and Health Investments

Limited Life Expectancy, Human Capital and Health Investments: Evidence from Huntington Disease ⬇️

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

Measuring the effects of therapy in Parkinson disease

Mendelian randomization of serum urate and parkinson disease progression

Milestones in huntington disease

Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments

Optimal Expectations and Limited Medical Testing: Evidence from Huntington Disease ⬇️

Optimal Expectations and Limited Medical Testing: Evidence from Huntington Disease: Corrigendum

Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study

Pharmacotherapy Use for Non-Motor Symptoms Among de novo Parkinson's Disease Parkinson's Progression Markers Initiative Participants

Phenotype-genotype discrepancies in the prospective Huntington at-risk observational study

Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions

Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10

Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial

Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts

Predictors of nursing home placement in Huntington disease

Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts

Preempting genetic discrimination and assaults on privacy: report of a symposium

Preparing for preventive clinical trials: the Predict-HD study

Rasagiline improves quality of life in patients with early Parkinson's disease